| Drug Type Biosimilar, Monoclonal antibody | 
| Synonyms Pertuzumab Biosimilar (Tanvex BioPharma, Inc.), 帕妥珠单抗生物类似药(泰福生技股份有限公司), TX-52 | 
| Target | 
| Action antagonists | 
| Mechanism HER2 antagonists(Receptor tyrosine-protein kinase erbB-2 antagonists), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePreclinical | 
| First Approval Date- | 
| Regulation- | 


| KEGG | Wiki | ATC | Drug Bank | 
|---|---|---|---|
| - | - | - | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Neoplasms | Preclinical | China  | 01 Feb 2025 | 






